INI-Resistance Mutations and Response to New INI-Containing Regimens
There has been only one salvage therapy study in which raltegravir (RAL)-experienced patients were treated with a second INI, dolutegravir (DTG). This phase II study has two cohorts receiving two different DTG doses.
In 18 subjects with viruses having mutations belonging to N155H or Y143 pathways, the mean plasma HIV-1 RNA decrease by day 11 was 1.8 log copies/mL. 3/5 subjects with Q148H+G140S had an RNA decrease of > 0.7 logs by day 11. None of 4 subjects with Q148 mutation plus >2 additional mutations at positions 74, 138, and 140 had an RNA decrease >0.7 logs.
